Rahmatnejad Kamran, Rapuano Christopher J, Ichhpujani Parul, Wizov Sheryl S, Moster Marlene R, Hark Lisa A, Katz L Jay
Glaucoma Research Center (K.R., S.S.W., M.R.M., L.A.H., L.J.K.), Wills Eye Hospital, Philadelphia, PA; and Cornea Department (C.J.R.), Wills Eye Hospital, Philadelphia, PA; Formerly Glaucoma Research Center (P.I.), Wills Eye Hospital, Philadelphia, PA; Currently Department of Ophthalmology (P.I.), Government Medical College and Hospital, Chandigarh, India.
Eye Contact Lens. 2018 Nov;44 Suppl 2:S93-S98. doi: 10.1097/ICL.0000000000000405.
To assess ocular surface changes in participants using latanoprost with benzalkonium chloride (Xalatan) and travoprost with SofZia (Travatan Z).
In this prospective, open-label, nonrandomized cohort study, participants were classified into two groups: group 1 (n=28) naive to glaucoma therapy, group 2 (n=27) on previous Xalatan monotherapy in both eyes. Both groups started (or continued) Xalatan in the right eye and Travatan Z in the left eye. Baseline, 1-, and 2-month measurements of tear breakup time (TBUT), corneal staining score, conjunctival staining score, conjunctival hyperemia score, tear production, and intraocular pressure were obtained. The Ocular Surface Disease Index questionnaire measured participants' comfort and dryness symptoms. Medication preference was recorded.
Data were collected from 55 participants. Tear breakup time at baseline and 1-month follow-up in group 1 was significantly longer than that of group 2 (P=0.005). At 2 months, there was no significant difference in TBUT between the two groups (P=0.779). Tear production in group 1 at all three time points was significantly higher than group 2 (P<0.05). Conjunctival staining score at 2 months in group 1 was significantly higher than group 2 (P=0.031). There was no significant difference in other parameters between the groups at any other time point. No significant difference in any parameter was found between Xalatan and Travatan Z (intragroup comparison).
Significant differences in ocular surface characteristics were detected between groups, but no significant difference was detected between participants treated with Xalatan and Travatan Z.
评估使用含苯扎氯铵的拉坦前列素（适利达）和含 SofZia 的曲伏前列素（苏为坦）的参与者的眼表变化。
在这项前瞻性、开放标签、非随机队列研究中，参与者被分为两组：第 1 组（n = 28）为初治青光眼患者，第 2 组（n = 27）为之前双眼均接受过适利达单药治疗的患者。两组均右眼开始（或继续）使用适利达，左眼开始（或继续）使用苏为坦。获取泪膜破裂时间（TBUT）、角膜染色评分、结膜染色评分、结膜充血评分、泪液分泌量和眼压的基线、1 个月和 2 个月测量值。眼表疾病指数问卷用于评估参与者的舒适度和干眼症状。记录用药偏好。
收集了 55 名参与者的数据。第 1 组基线和 1 个月随访时的泪膜破裂时间显著长于第 2 组（P = 0.005）。在 2 个月时，两组之间的 TBUT 无显著差异（P = 0.779）。第 1 组在所有三个时间点的泪液分泌量均显著高于第 2 组（P < 0.05）。第 1 组在 2 个月时的结膜染色评分显著高于第 2 组（P = 0.031）。在其他任何时间点，两组之间的其他参数均无显著差异。在适利达和苏为坦之间（组内比较），任何参数均未发现显著差异。
两组之间在眼表特征方面存在显著差异，但在使用适利达和苏为坦治疗的参与者之间未检测到显著差异。
